Insulet Announces Pricing of Senior Notes Due 2033

Insulet Announces Pricing of Senior Notes Due 2033

ACTON, Mass., March 18, 2025 Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company ), the global leader in tubeless

insulin pump technology with its Omnipod brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the

Notes ). The Notes will bear interest at an annual rate of 6.50% and will mature on April 1, 2033, unless earlier redeemed or repurchased. The closing of the private placement is expected to occur on March 20, 2025, subject to

customary closing conditions.

The Company estimates that the net proceeds from the Notes offering will be approximately $444.4 million, after deducting

discounts and before estimated offering expenses payable by the Company.

The Company intends to use the net proceeds from the Notes offering, together

with cash on hand and potentially cash from partially terminating the Company s existing capped call transactions relating to the Company s existing 0.375% Convertible Senior Notes due 2026 (the Convertible Senior Notes ), (i)

to finance the redemption, repurchase, repayment, satisfaction and discharge or other payment of all or a portion of the Convertible Senior Notes, which may include one or more repurchases pursuant to privately negotiated transactions, and the

payment of accrued and unpaid interest thereon, (ii) to pay any fees, costs and expenses relating to the offering of the Notes and the Company s previously announced credit agreement transactions (if applicable) and/or (iii) for

general corporate purposes.

The Notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to

Rule 144A under the Securities Act of 1933, as amended (the Securities Act ) and only to non-U.S. persons outside the United States pursuant to Regulation S.

The Notes have not been registered under the Securities Act or applicable state securities laws. As a result, the Notes may not be offered or sold within the

United States or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws.

This press release does not and will not constitute an offer to sell or a solicitation of an offer to buy any securities nor will there be any sale of these

securities in any state in which such offer, solicitation or sale would be unlawful under the securities laws of such state. Any offer of the Notes will be made only by means of a private offering memorandum. This press release does not and will not

constitute an offer to repurchase the Convertible Senior Notes, nor do the statements herein constitute a notice of redemption under the indenture governing the Convertible Senior Notes.

About Insulet Corporation:

(NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides

a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a

needle. Insulet s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily

injections, zero fingersticks, and can be controlled by a compatible personal smartphone or the Omnipod Controller. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Forward-Looking Statements:

This press release contains forward-looking statements concerning Insulet s expectations, anticipations, intentions, beliefs or strategies regarding the

future, including the offering of the Notes and the use of proceeds from the offering of the Notes. These forward-looking statements are based on Insulet s current expectations and beliefs concerning future developments and their potential

effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Insulet s

control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in Insulet s Annual Report on

Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2025 in the section entitled Risk Factors , and in its other filings from time to time with the Securities

and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

2025 Insulet Corporation. Omnipod is a registered

endorsement or imply a relationship or other affiliation.

Senior Director, Investor Relations

Angela Geryak Wiczek

Senior Director, Corporate Communications